Company Description

Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.

It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications.

The company was founded in 2011 and is headquartered in Copenhagen, Denmark.

Damora Therapeutics, Inc.

Country	Denmark
Founded	2011
IPO Date	Oct 29, 2020
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	Sherwin Sattarzadeh

Contact Details

Address: Ole Maaloes Vej 3, Copenhagen N Copenhagen, 2200 Denmark
Phone	45 70 70 52 10
Website	galecto.com

Stock Details

Ticker Symbol	DMRA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1800315
ISIN Number	US36322Q2066
Employer ID	37-1957007
SIC Code	2834

Key Executives

Name	Position
Lori C. Firmani	Chief Financial Officer
Garrett Winslow Esq.	Senior Vice President, General Counsel and Corporate Secretary
Sherwin Sattarzadeh	Interim Principal Executive Officer and Chief Operating Officer
Ulf J. Nilsson Ph.D.	Co-Founder
Dr. Hakon Leffler M.D., Ph.D.	Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.	Co-Founder
Dr. Becker Hewes M.D.	Chief Medical Officer

Latest SEC Filings

Date	Type	Title
Mar 10, 2026	8-K	Current Report
Mar 6, 2026	SCHEDULE 13G/A	Filing
Feb 17, 2026	SCHEDULE 13G	Filing
Feb 17, 2026	SCHEDULE 13G	Filing
Feb 11, 2026	SCHEDULE 13D/A	Filing
Feb 11, 2026	8-K	Current Report
Feb 11, 2026	424B5	Filing
Feb 10, 2026	424B5	Filing
Feb 10, 2026	S-3ASR	Automatic shelf registration statement of securities of well-known seasoned issuers
Feb 10, 2026	8-K	Current Report

View All SEC Filings